View source for Niraparib and abiraterone (Akeega)

==Mechanism of action==
A fixed dose combination of niraparib and abiraterone. Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2, which are involved in DNA repair. Inhibiting PARP-1 and PARP-2 may result in formation of PARP-DNA complexes, DNA damage, apoptosis, and cell death. PARP proteins utilize base-excision repair (BER) to identify and repair single strand DNA breaks. Abiraterone is an antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.

==Diseases for which it is established==
*[[Prostate cancer, BRCA-mutated]]

==History of changes in FDA indication==
*2023-08-11: Initial approval with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant [[prostate cancer]] (mCRPC), as determined by an FDA-approved test. ''(Based on MAGNITUDE)''
==History of changes in EMA indication==
*2023-04-19: Initial authorisation for treatment of adult patients with [[prostate cancer]].
==Also known as==
*'''Code name:''' CJNJ-67652000
*'''Brand name:''' Akeega

[[Category:Drugs]]
[[Category:Oral medications]]
[[Category:Mutation-specific medications]]
[[Category:PARP1 inhibitors]]
[[Category:PARP2 inhibitors]]
[[Category:CYP17 inhibitors]]

[[Category:Prostate cancer medications]]

[[Category:EMA approved in 2023]]
[[Category:FDA approved in 2023]]